Abivax (ABVX) Quality Analysis

ABVX GoodMoat Verdict

Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.

Run Stock X-Ray →

ABVX Profitability

Profitability trend analysis coming soon

ABVX Growth

Growth trend analysis coming soon

ABVX Financial Health

Financial health indicators coming soon

ABVX Quality & Fundamental Analysis

Abivax (ABVX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Abivax's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.

Abivax has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -7389.63% and a return on equity (ROE) of -72.96%. Return on assets (ROA) stands at -56.84%.

The debt-to-equity ratio is 0.07, with a current ratio of 8.75. Operating margin is -5384.14%.

GoodMoat's quality analysis uses AI-powered insights to evaluate whether Abivax is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.